Kidney replacement therapy and mortality in metformin-associated lactic acidosis with acute kidney injury (2015–2021): a multi-year cohort study
Open Access
- 24 November 2025
- journal article
- Published by Taylor & Francis in Renal Failure
- Vol. 47 (1) , 2586333
Abstract
Metformin-associated lactic acidosis (MALA) is a life-threatening complication. Treatment of MALA includes supportive care and dialysis. However, the role of kidney replacement therapy (KRT) in MALA is controversial, this study aimed to compare patient and kidney outcomes between MALA-acute kidney injury (AKI) patients receiving KRT (KRT group) vs. supportive care (supportive care group). A cohort study was conducted on 143 adult patients with MALA-AKI from 1 January 2015 to 31 December 2021. The primary outcome was the patient mortality rate and predictive factors of mortality, while the secondary outcomes were kidney survival. The overall mortality rate in our MALA-AKI cohort was 20.3% (29 of 143 patients). The KRT group had a lower mortality rate compared with the supportive care group (16% vs. 28.6%, P = 0.006). Among patients who received dialysis, hemodialysis (HD) was associated with a lower mortality rate compared with acute peritoneal dialysis (APD) (8.9% vs. 30.8%, P = 0.044). Patients who received late KRT (≥6 h) had a trend toward higher mortality compared with those who received early KRT (P = 0.002), prolonged prothrombin time (HR 1.20, P = 0.001) and higher Sequential Organ Failure Assessment (SOFA) scores (HR 1.26, P = 0.006). MALA-AKI was associated with high mortality, and KRT reduced mortality rate when compared with supportive care. HD was the most effective treatment in MALA-AKI, early KRT initiation (<6 h) showed a trend toward lower mortality and oliguria, prolonged prothrombin time, and higher SOFA scores were identified as prognostic markers.Keywords
This publication has 32 references indexed in Scilit:
- Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes MellitusAnnals of Internal Medicine, 2012
- Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes StudyDiabetes Care, 2012
- Management of Metformin-Associated Lactic Acidosis by Continuous Renal Replacement TherapyPLOS ONE, 2011
- Life threatening lactic acidosisBMJ, 2010
- Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus2010
- Metformin-associated lactic acidosis: A prognostic and therapeutic study*Critical Care Medicine, 2009
- Metformin-associated lactic acidosis in an intensive care unitCritical Care, 2008
- Serial Evaluation of the SOFA Score to Predict Outcome in Critically Ill PatientsJAMA, 2001
- Metformin and lactic acidosis in diabetic humansDiabetes, Obesity and Metabolism, 2000
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.1998